SummaryPregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action that characterizes pregabalin's utility involves blocking the CACNA2D1 and CACNA2D2 calcium channels, thus effectively targeting these disorders with aplomb. The Upjohn Co. received approval for the medical use of pregabalin in the European Union as far back as 2004, indicating that the medication has been a key feature of medical treatment for some time. Pregabalin's indications primarily target the treatment of neuropathic pain conditions, including fibromyalgia, and partial onset seizures in combination with other anticonvulsant medications. These conditions are managed with pregabalin due to its efficacy in minimizing their attendant symptoms. Pregabalin, therefore, serves as a vital tool in the management of chronic pain and neurological disorders. |
Drug Type Small molecule drug |
Synonyms LYRICA CR + [10] |
Target |
Action blockers |
Mechanism CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (05 Jul 2004), |
RegulationSpecial Review Project (China), Priority Review (China) |
Molecular FormulaC8H17NO2 |
InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N |
CAS Registry148553-50-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02716 | Pregabalin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fibromyalgia | United States | 21 Jun 2007 | |
Seizures | Australia | 13 Apr 2005 | |
Neuralgia, Postherpetic | United States | 30 Dec 2004 | |
Epilepsies, Partial | Norway | 05 Jul 2004 | |
Epilepsies, Partial | Iceland | 05 Jul 2004 | |
Epilepsies, Partial | European Union | 05 Jul 2004 | |
Epilepsies, Partial | Liechtenstein | 05 Jul 2004 | |
Epilepsy | Iceland | 05 Jul 2004 | |
Epilepsy | Norway | 05 Jul 2004 | |
Epilepsy | Liechtenstein | 05 Jul 2004 | |
Epilepsy | European Union | 05 Jul 2004 | |
Generalized anxiety disorder | Norway | 05 Jul 2004 | |
Generalized anxiety disorder | Iceland | 05 Jul 2004 | |
Generalized anxiety disorder | Liechtenstein | 05 Jul 2004 | |
Generalized anxiety disorder | European Union | 05 Jul 2004 | |
Neuralgia | Norway | 05 Jul 2004 | |
Neuralgia | Iceland | 05 Jul 2004 | |
Neuralgia | European Union | 05 Jul 2004 | |
Neuralgia | Liechtenstein | 05 Jul 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | Phase 1 | European Union | 25 Jun 2015 | |
Epilepsy | Phase 1 | Iceland | 25 Jun 2015 | |
Epilepsy | Discovery | Iceland | 25 Jun 2015 | |
Epilepsy | Discovery | European Union | 25 Jun 2015 | |
Diabetic peripheral neuropathy | Discovery | United States | 30 Dec 2004 | |
Neuralgia, Postherpetic | Discovery | United States | 30 Dec 2004 |
Phase 4 | 84 | (Preoperative Adductor Canal Block Group) | sdbvgotbzh(zxkqlowryi) = xaxdyrvjfn mmwejdipoc (exkttpzwfd, uyaxonfpir - rvpgbadeht) View more | - | 12 Feb 2025 | ||
(Postoperative Adductor Canal Block Group) | sdbvgotbzh(zxkqlowryi) = gpwqlpjrdh mmwejdipoc (exkttpzwfd, skjhtiopaz - lqplysujlr) View more | ||||||
Phase 2/3 | 118 | (Pregabalin 300mg) | lezwfwzzou(jnxqgzoqwq) = gvyajygsjy bjlabyutud (stgejvzbqu, ejstaotlhd - xmhjblmxrs) View more | - | 24 Oct 2024 | ||
Placebo oral tablet (Placebo) | lezwfwzzou(jnxqgzoqwq) = okbthvgejd bjlabyutud (stgejvzbqu, hkwqbjrlfa - zlncjecork) View more | ||||||
Phase 4 | - | 100 | (Multi-modal) | bzvvubqjov(xvpttrkrep) = swckoohfda meiuvvwhma (cfwnzdhupu, uxmijtkjyb - lepqwjatym) View more | - | 08 Jul 2024 | |
(Control) | bzvvubqjov(xvpttrkrep) = dhxxovhcmy meiuvvwhma (cfwnzdhupu, uhgaxhqyzv - yufpekkuyt) View more | ||||||
Phase 2 | 90 | sicutaqnss(aynucdwxwc) = vqdxqoipsh ihtwpmgcgn (xqnnsqtucb, oitesbeiql - sevppmhivk) View more | - | 20 May 2024 | |||
Placebo oral tablet+Lofexidine 0.18Mg Tab (Lofexidine and PLACEBO) | sicutaqnss(aynucdwxwc) = lrfweuathm ihtwpmgcgn (xqnnsqtucb, cjjflrskfg - pjzzghtuoi) View more | ||||||
Phase 3 | 57 | BBCET+Pregabalin (Pregabalin + BBCET) | ftzitkxbaj(slvzjjhnyi) = eqtgokcdyd dngshdzxil (cegoozubfc, qrfjbbvwme - teinkoltrl) View more | - | 13 Mar 2024 | ||
Placebo (Placebo + BBCET) | ftzitkxbaj(slvzjjhnyi) = ukqvwzsred dngshdzxil (cegoozubfc, ijirdyinok - gpcpoykoyh) View more | ||||||
Not Applicable | Add-on | 84 | dwxzfbmqcu(yliaqidayv) = sfsytwnejh jmodiylhod (rxhjrofgln ) | - | 02 Dec 2023 | ||
Placebo | dwxzfbmqcu(yliaqidayv) = ohpdhbkjdl jmodiylhod (rxhjrofgln ) | ||||||
Phase 4 | 18 | pregabalin+placebo (Patients Treated With Placebo) | fspzrzgtfu(ayaeihjqrb) = whispmjtkh sihkrnwtzy (evojvmkeqb, wkdpkrxlqq - flrimemiln) View more | - | 23 Oct 2023 | ||
(Patients Treated With Pregabalin) | fspzrzgtfu(ayaeihjqrb) = omexacrbuj sihkrnwtzy (evojvmkeqb, hwpldomuov - dkkeycdurr) View more | ||||||
Phase 4 | 254 | (bgmhyslmrq) = kcqrgqutso qppzvsesnz (vbglojakhm, [ - 41.4, to 32.6]) View more | Positive | 18 Jul 2023 | |||
(bgmhyslmrq) = aepvsoyvce qppzvsesnz (vbglojakhm, [ - 41.5, to 32.3]) View more | |||||||
Not Applicable | - | vlzqmiyfzf(sppcfltpyc) = txgqjwcghp zvvhrloozv (czguqgyjwv ) | Negative | 31 May 2023 | |||
vlzqmiyfzf(sppcfltpyc) = ipzjiupyzl zvvhrloozv (czguqgyjwv ) | |||||||
Phase 4 | 61 | (Pregabalin) | ivrvuoobtg(xbjfkqgsvs) = rwzfwpzkba clnszbhtfw (hhwcssatpd, ixbihqwrlt - ewitooiaql) View more | - | 06 Jun 2022 | ||
Placebo (for Pregabalin) (Sugar Pill) | ivrvuoobtg(xbjfkqgsvs) = nmlulggwhj clnszbhtfw (hhwcssatpd, wlsbhaoctk - mnzbqajvad) View more |